Ensovibep, a SARS‐CoV‐2 Antiviral Designed Ankyrin Repeat Protein, is Safe and Well Tolerated in Healthy Volunteers: Results of a First‐in‐human, Ascending Single‐dose Phase 1 Study
British Journal of Clinical Pharmacology（2023）
Key words
antiviral,COVID-19,DARPin,ensovibep,omicron,variants of concern
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined